TY - JOUR
T1 - Toxicities of Human Recombinant Interferon-α2 in Patients with Advanced Prostate Carcinoma
AU - Chang, Alex Y.C.
AU - Fisher, Hugh A.G.
AU - Spiers, Alexander S.D.
AU - Boros, Laszlo
PY - 1986/12
Y1 - 1986/12
N2 - Nine patients with hormone-resistant prostate carcinoma were treated with subcutaneous injection of recombinant human interferon-α2 (rHuIFN-α2), 5-10 χ 106 U/m2, three times a week. One patient had a mixed clinical response with reduction of bone pain. The study was closed due to intolerable grade III and IV toxicities including weight loss (8/9), fatigue/malaise (7/9), central nervous system toxicity (4/9), leukopenia (3/9), and uncontrollable nausea and vomiting (2/9). These toxicities resulted in deterioration of performance status. It is concluded that rHuIFN-α2, at least at the dose and schedule studied, should not be used for the treatment of patients with hormone-resistant prostate carcinoma.
AB - Nine patients with hormone-resistant prostate carcinoma were treated with subcutaneous injection of recombinant human interferon-α2 (rHuIFN-α2), 5-10 χ 106 U/m2, three times a week. One patient had a mixed clinical response with reduction of bone pain. The study was closed due to intolerable grade III and IV toxicities including weight loss (8/9), fatigue/malaise (7/9), central nervous system toxicity (4/9), leukopenia (3/9), and uncontrollable nausea and vomiting (2/9). These toxicities resulted in deterioration of performance status. It is concluded that rHuIFN-α2, at least at the dose and schedule studied, should not be used for the treatment of patients with hormone-resistant prostate carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=0022897894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022897894&partnerID=8YFLogxK
U2 - 10.1089/jir.1986.6.713
DO - 10.1089/jir.1986.6.713
M3 - Article
C2 - 3572090
AN - SCOPUS:0022897894
SN - 0197-8357
VL - 6
SP - 713
EP - 715
JO - Journal of Interferon Research
JF - Journal of Interferon Research
IS - 6
ER -